• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Seasonal influenza vaccine effectiveness in people with asthma: a national test-negative design case-control study

tetano

Editor, Senior Moderator
Clin Infect Dis. 2019 Nov 5. pii: ciz1086. doi: 10.1093/cid/ciz1086. [Epub ahead of print] [h=1]Seasonal influenza vaccine effectiveness in people with asthma: a national test-negative design case-control study.[/h]
Vasileiou E, Sheikh A[SUP]1[/SUP], Butler CC[SUP]2[/SUP], Robertson C[SUP]3[/SUP], Kavanagh K[SUP]4[/SUP], Englishby T[SUP]4[/SUP], Lone NI[SUP]1[/SUP], von Wissmann B[SUP]5[/SUP], McMenamin J[SUP]5[/SUP], Ritchie LD[SUP]6[/SUP], Schwarze J[SUP]7[/SUP], Gunson R[SUP]8[/SUP], Simpson CR[SUP]9[/SUP].
[h=3]Author information[/h] 1 Asthma UK Centre for Applied Research, Usher Institute, The University of Edinburgh, Edinburgh, UK. 2 Nuffield Department of Primary Care Health Sciences, Oxford University, New Radcliffe House, Radcliffe Observatory Quarter, Woodstock Road, Oxford, UK and Cardiff University, Institute of Primary Care and Public Health, Cardiff, UK. 3 Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK and Health Protection Scotland, Glasgow, UK. 4 Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK. 5 Health Protection Scotland, NHS National Services Scotland, Meridian Court, Glasgow, UK. 6 Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK. 7 Centre for Inflammation Research, Queen's Medical Research Institute, Child Life and Health, The University of Edinburgh, Edinburgh, UK. 8 West of Scotland Specialist Virology Centre, Glasgow, UK. 9 School of Health, Faculty of Health, Victoria University of Wellington, Wellington, New Zealand and Asthma UK Centre for Applied Research, Usher Institute, The University of Edinburgh, Edinburgh, UK.

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza infection is an important trigger of asthma attacks. Influenza vaccination has the potential to reduce the incidence of influenza in people with asthma, but uptake remains persistently low, partially reflecting concerns about vaccine effectiveness (VE).
[h=4]METHODS:[/h] We conducted a test-negative design case-control study to estimate the effectiveness of influenza vaccine in children and adults with asthma in Scotland over six influenza seasons (2010/11 to 2015/16). We used individual patient level data from 223 primary care practices which yielded 1,830,772 patient-years of data, which were linked with hospital and virological (n=5,910 swabs) data.
[h=4]RESULTS:[/h] Vaccination was associated with an overall 55.0% (95% confidence interval (CI): 45.8-62.7) reduction in the risk of a laboratory-confirmed influenza infection in people with asthma over the six seasons. There was substantial variation in VE between seasons, influenza strains and age groups. The highest VE (76.1%; 95% CI: 55.6-87.1) was found in 2010/11 season where the A(H1N1) strain dominated and there was a good antigenic vaccine match. High protection was observed against A(H1N1) (e.g. 2010/11: 70.7%; 95%CI: 32.5-87.3) and B strains (e.g. 2010/11: 83.2%; 95%CI: 44.3-94.9), but there was lower protection for the A(H3N2) strain (e.g. 2014/15: 26.4%; 95%CI: -12.0-51.6). The highest VE against all viral strains was observed in adults aged 18-54 years (57.0%; 95%CI: 42.3-68.0).
[h=4]CONCLUSION:[/h] Influenza vaccination gave meaningful protection against laboratory-confirmed influenza in people asthma across all six seasons. Strategies to boost influenza vaccine uptake has the potential to substantially reduce influenza triggered asthma attacks.
? The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.


[h=4]KEYWORDS:[/h] asthma; influenza; laboratory confirmed influenza; vaccination

PMID: 31688921 DOI: 10.1093/cid/ciz1086
 
Back
Top Bottom